Cisplatin Binding Sites on Human Albumin*

Reactions of cisplatin (cis-[PtCl2(NH3)2]) with albumin are thought to play an important role in the metabolism of this anticancer drug. They are investigated here via (i) labeling of cisplatin with 15N and use of two-dimensional1H,15N NMR spectroscopy, (ii) comparison of natural human serum albumin with recombinant human albumin (higher homogeneity and SH content), (iii) chemical modification of Cys, Met, and His residues, (iv) reactions of bound platinum with thiourea, and (v) gel filtration chromatography. In contrast to previous reports, it is shown that the major sulfur-containing binding site involves Met and not Cys-34, and also a N ligand, in the form of an S,N macrochelate. Additional monofunctional adducts involving other Met residues and Cys-34 are also observed. During the later stages of reactions of cisplatin with albumin, release of NH3 occurs due to the strong trans influence of Met sulfur, which weakens the Pt-NH3 bonds, and protein cross-linking is observed. The consequences of these findings for the biological activity of cisplatin-albumin complexes are discussed.

[1]  P. Kuchel,et al.  Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR , 1990 .

[2]  S. Lippard,et al.  Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. , 1996, Biochemistry.

[3]  J. H. Viles,et al.  Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. , 1994, European journal of biochemistry.

[4]  J. Keeler,et al.  Minimizing Sensitivity Losses in Gradient-Selected 15N-1H HSQC Spectra of Proteins , 1994 .

[5]  J. Verweij,et al.  Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. , 1994, British Journal of Cancer.

[6]  M. Aapro Radiotherapy and drugs: 'setrons' once again. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Sadler,et al.  1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34 , 1995, FEBS letters.

[8]  P. Sadler,et al.  Platination of a GG site on single-stranded and double-stranded forms of a 14-base oligonucleotide with diaqua cisplatin followed by NMR and HPLC -- influence of the platinum ligands and base sequence on 5'-G versus 3'-G platination selectivity. , 1997, European journal of biochemistry.

[9]  H. Zeng,et al.  FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. , 1997, International journal of biological macromolecules.

[10]  M. Yamamoto,et al.  In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. , 1995, Journal of pharmaceutical sciences.

[11]  L. Kèlland Platinum anticancer drugs , 1994 .

[12]  F. Gurd,et al.  Nuclear magnetic resonance studies of sperm whale myoglobin specifically enriched with 13C in the methionine methyl groups. , 1976, The Journal of biological chemistry.

[13]  N. Hadjiliadis,et al.  NMR Study of the Interaction of Platinum Salts with a Tetrapeptide Containing Cysteinyl Residues , 1994 .

[14]  T. Wright,et al.  Interaction of natural and synthetic albumin polymers with hepatocytes , 1987, Hepatology.

[15]  H. Ogata,et al.  Decomposition Kinetics of Cisplatin in Human Biological Fluids , 1996, The Journal of pharmacy and pharmacology.

[16]  P. Sadler,et al.  Hydrolysis products of cisplatin: pKa determinations via[1H, 15N] NMR spectroscopy , 1992 .

[17]  W. E. Lindup,et al.  Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. , 1994, Biochemical pharmacology.

[18]  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. , 1992, British journal of clinical pharmacology.

[19]  G. Berthon Handbook of metal-ligand interactions in biological fluids, bioinorganic chemistry , 1995 .

[20]  P. Sadler,et al.  Solvolysis of cis-[Pt(NH3)2Cl2] in dimethyl sulphoxide and reactions of glycine with [PtCl3(Me2SO)]– as probed by 195Pt nuclear magnetic resonance shifts and 195Pt–15N coupling constants , 1977 .

[21]  P. Sadler,et al.  Effects of chemical shift anisotropy and 14N coupling on the 1H and 195Pt nuclear magnetic resonance spectra of platinum complexes , 1982 .

[22]  R. Freeman A handbook of nuclear magnetic resonance , 1987 .

[23]  E. Espinosa,et al.  Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. , 1995, Lung cancer.

[24]  K. Dardoufas,et al.  Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine. , 1997, Journal of chemotherapy.

[25]  R. Lange,et al.  Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.

[26]  Peter J. Sadler,et al.  Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. , 1996, Inorganic chemistry.

[27]  N. W. Flodin Handbook of Metal-Ligand Interactions in Biological Fluids , 1996 .

[28]  S. Ito,et al.  Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. , 1991, Chemical & pharmaceutical bulletin.

[29]  E. W. Miles Modification of histidyl residues in proteins by diethylpyrocarbonate. , 1977, Methods in enzymology.

[30]  A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer. , 1997, American journal of clinical oncology.

[31]  M. Friedman,et al.  The effects of platinum complexes on seven enzymes. , 1979, Biochimica et biophysica acta.

[32]  S. Pizzo,et al.  Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule. , 1983, The Journal of biological chemistry.

[33]  P. Jocelyn Spectrophotometric assay of thiols. , 1987, Methods in enzymology.

[34]  P. Sadler,et al.  Stabilization of monofunctional platinum–nucleotide adducts: reactions of N-acetyl-L-methionine complexes with guanosine 5′-monophosphate and guanylyl(3′–5′)guanosine , 1996 .

[35]  S. Pizzo,et al.  Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. , 1988, Journal of inorganic biochemistry.

[36]  P. Sadler,et al.  Studies of platinum(II) methionine complexes : metabolites of cisplatin , 1992 .

[37]  B. Keppler Metal complexes in cancer chemotherapy , 1993 .

[38]  J. Schacht,et al.  Diet is a risk factor in cisplatin ototoxicity , 1995, Hearing Research.

[39]  S. Urien,et al.  Drug Binding in Plasma , 1994, Clinical pharmacokinetics.

[40]  Hans Robert Kalbitzer,et al.  Distribution of chemical shifts in 1H nuclear magnetic resonance spectra of proteins , 1988 .

[41]  A. Eastman Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.

[42]  D. Eisenberg,et al.  PtCl24-: a methionine-specific label for protein crystallography. , 1969, Journal of molecular biology.

[43]  P. Sadler,et al.  Proton NMR studies of bovine serum albumin. Assignment of spin systems. , 1992, European journal of biochemistry.

[44]  D C Carter,et al.  Structure of serum albumin. , 1994, Advances in protein chemistry.

[45]  W Wolf,et al.  Preparation and metabolism of a cisplatin/serum protein complex. , 1980, Chemico-biological interactions.

[46]  A. J. Shaka,et al.  Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients , 1995 .

[47]  S. Ito,et al.  Disulfide bond cleavage of human serum albumin and alterations of its secondary structure by cis-diamminedichloroplatinum(II) , 1992 .

[48]  P. Sadler,et al.  Chelate-ring-opened adducts of[Pt(en)(Me-Mal-O,O′)](en = ethane-1,2-diamine,Me-Mal = 2-methylmalonate) with methionine derivatives:relevance to the biological activity of platinum anticanceragents , 1997 .

[49]  Stephen B. Howell Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.

[50]  A. Habeeb [37] Reaction of protein sulfhydryl groups with Ellman's reagent. , 1972, Methods in enzymology.

[51]  D. Carter,et al.  Atomic structure and chemistry of human serum albumin , 1992, Nature.

[52]  R. Borch,et al.  Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Kuduk-Jaworska,et al.  Impact of K2PtCl4 on the structure of human serum albumin and its binding ability of heme and bilirubin. , 1994, Journal of inorganic biochemistry.

[54]  R. F. Chen,et al.  Removal of fatty acids from serum albumin by charcoal treatment. , 1967, The Journal of biological chemistry.

[55]  S. Pizzo,et al.  Inactivation of the plasma protease inhibitor alpha 2-macroglobulin by the antitumor drug cis-dichlorodiamineplatinum(II). , 1981, The Journal of biological chemistry.

[56]  D. Bowdler,et al.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. , 1991, British journal of clinical pharmacology.

[57]  S. Aggarwal,et al.  Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention , 1997, Cancer Chemotherapy and Pharmacology.

[58]  M. Esposito,et al.  Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. , 1988, Anticancer Research.

[59]  G. Falkson,et al.  Neoadjuvant cisplatin plus ifosfamide in patients with stage IIB cervical cancer: a single center phase II study , 1997 .

[60]  H. Pinedo,et al.  Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. , 1986, Clinical chemistry.

[61]  C. Briand,et al.  Influence of time and chloride ions on the interaction of cisplatin with human albumin in‐vitro , 1987, The Journal of pharmacy and pharmacology.

[62]  N. Dodsworth,et al.  Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation , 1996, Biotechnology and applied biochemistry.

[63]  A. Jones,et al.  Uptake and metabolism of polymerized albumin by rat liver. Role of the scavenger receptor. , 1988, Gastroenterology.